About FUSEN PHARM Company

According to the Frost & Sullivan report, in terms of revenue, we are the leading brand of 2016 Shuanghuanglian cold medicine, while Shuanghuanglian cold medicine was the largest category in the 2016 proprietary cold medicine market, with a market share of 9.1%. According to the same source, in terms of revenue in 2016, we were the largest manufacturer of Shuanghuanglian cold medicine and the eighth largest manufacturer of proprietary cold medicines, with market shares of 32.1% and 3.1% respectively. According to the Frost & Sullivan report, in terms of revenue, one of our main products, Shuanghuanglian Oral Liquid, was also the largest drug category in the 2016 proprietary cold medicine market, with a market share of 5.3%. In addition to providing our core product, Shuanghuanglian cold medicine, we are engaged in the development, production and sale of a variety of proprietary Chinese and Western medicine products for the treatment of colds and fevers, cardiovascular diseases and anemia. According to the Frost & Sullivan Report, most of our products also enjoy leading market share in their respective markets. Our headquarters is strategically located in Xichuan County, Henan Province. According to Frost & Sullivan's report, in terms of 2016 production, Xichuan County is the third largest producer of honeysuckle in China, and honeysuckle is one of the main raw materials for the production of diphylloxacin drugs. According to the same report from the same year, honeysuckle production in Xichuan County accounts for about 23.2% of the country's honeysuckle production. We believe that the favorable location of the production base in Xichuan County will help us obtain a stable supply of high-quality raw materials, ensure product quality, and control procurement costs. Our advanced pharmaceutical production facility is also located in Xichuan County. As of September 30, 2017, we have 18 GMP certified production lines that can produce more than 71 types of proprietary Chinese and Western medicine products according to the five dosage forms specified by GMP, including small-volume injections (including drug pre-treatment and extraction), oral liquids, tablets, capsules and granules (including drug pre-treatment and extraction). We believe that this strong production capacity allows us to achieve economic benefits based on meeting market needs. At the same time, our in-house production of major packaging materials also allows us to integrate procurement and production packaging processes in strategically located production base facilities to achieve synergies, including better control of production costs and product quality. We have established an extensive sales and distribution network across the country, covering 31 provinces, autonomous regions and municipalities directly under the Central Government of China. As of September 30, 2017, we had 257 sales representatives at our headquarters and 17 cities, who managed a sales and distribution network composed of 1,499 dealers and 144 direct sales customers (mainly pharmacy chains). We usually seek long-term partnerships with dealers and pharmacy chains that are familiar with the local market and have a good reputation. As of September 30, 2017, more than 500 dealers had business relationships with us for no less than seven years, and during the track record period, the revenue they generated accounted for about half of our revenue. Our extensive sales and distribution network also penetrates deep into our local terminal market in Henan Province, which is strategically positioned based on population density, and our markets in central China (including Hubei, Hunan, Jiangxi, Hebei and Shanxi provinces, as well as the municipalities of Beijing and Tianjin), which provided revenue contributions of 57.4%, 55.7% and 56.6% in 2015, 2016 and the nine months ending September 30, 2017, respectively.